文献速递淋巴瘤造血干细胞移植与细胞治疗

供者类型、干细胞来源与预处理对淋巴瘤单倍体移植结局的影响

Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study.
PubMed 文献 · Br J Haematol · 2019-09-09

该LWP-EBMT研究纳入474例接受单倍体移植后环磷酰胺的成人淋巴瘤患者,中位随访32个月。多因素分析显示无进展生存和总生存主要受疾病状态和淋巴瘤亚型影响,支持使用任何一级单倍体亲属供者。

要点

  • 完全缓解状态移植改善PFS和OS,CMV供受者均阳性负面影响两者。
  • FL、HL和PTCL的PFS较好,HL和PTCL的OS较好。
  • 使用超出一级亲属的单倍体供者负向影响OS。

核心结论

  • PFS和OS主要受疾病状态和淋巴瘤亚型影响,支持使用任何一级单倍体家族成员作为供者。

研究设计与样本

  • LWP-EBMT研究纳入474例接受单倍体移植后环磷酰胺的成人淋巴瘤患者,中位随访32个月。

主要发现

  • 急性GVHD 2-4级在子女供者或骨髓细胞时较低。
  • 广泛慢性GVHD在移植时部分缓解、姐妹供者、超出一级亲属的单倍体供者或男性患者女性供者时较高。
  • FL、HL和PTCL的PFS较好,HL和PTCL的OS较好。
  • 移植时完全缓解改善PFS和OS,CMV供者阳性/受者阳性负向影响两者。
  • 超出一级亲属的单倍体供者负向影响OS。

关键数值与推荐

  • 供者年龄、性别、HLA错配、ABO不合不影响PFS或OS,但超出一级亲属的单倍体供者负向影响OS。

临床怎么用

  • 优先选择一级亲属单倍体供者,关注疾病状态和淋巴瘤亚型对预后的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Haploidentical stem cell transplantation (haploSCT) is becoming a major transplant modality for lymphoma. To assess the effects of donor characteristics, stem cell source and conditioning on outcomes, we identified 474 adults with Hodgkin (HL; 240), peripheral T-cell (PTCL; 88), diffuse large B-cell (77), mantle cell (40) or follicular lymphoma (FL; 29), who received haploSCT with post-transplant cyclophosphamide. Median follow-up of alive patients was 32 months. On multivariate analysis, acute graft-versus-host disease (GVHD) grade 2-4 was lower with offspring donors or bone marrow cells, whereas extensive chronic GVHD was higher in partial response at haploSCT or when using sisters, haploidentical donors beyond first degree, or female donors in male patients. Progression-free survival (PFS) was better for FL, HL and PTCL, whereas overall survival (OS) was better for HL and PTCL. Complete remission at haploSCT improved PFS and OS whereas these were negatively affected by cytomegalovirus donor positive/recipient positive status. No other donor characteristics (age, gender, human leucocyte antigen mismatch, ABO incompatibility) affected PFS or OS except use of haploidentical donors beyond first degree, which negatively affected OS. PFS and OS are mostly influenced by disease status and lymphoma subtype, supporting the use of any first degree haploidentical family member as a donor.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Bazarbachi A, Boumendil A, Finel H, et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. Br J Haematol. 2019. PMID: 31498883. doi:10.1111/bjh.16182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。